Edition:
United States

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.41USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.41
Open
$3.41
Day's High
$3.49
Day's Low
$3.33
Volume
50,098
Avg. Vol
23,463
52-wk High
$12.09
52-wk Low
$3.26

Summary

Name Age Since Current Position

Jason Aryeh

48 2012 Independent Chairman of the Board

Michael Price

59 2017 Chief Financial Officer, Senior Vice President

Gregory Perry

56 2016 Chief Financial and Administrative Officer

Jeffrey Hackman

55 2017 Chief Operating Officer, Executive Vice President

Barbara Chan

53 2016 Chief Accounting Officer

Suzanne Bruhn

53 2017 Director

Mark Corrigan

60 2017 Director

Mark DiPaolo

2017 Director

Kevin Kotler

2016 Director

John Orloff

59 2017 Director

Donald Stern

2016 Director

Anne VanLent

2016 Director

Stephen Sabba

57 2012 Independent Director

John Thomas

62 2012 Independent Director

Biographies

Name Description

Jason Aryeh

Mr. Jason M. Aryeh is an Independent Chairman of the Board of the company. Currently, Mr. Aryeh is also the Founder and Managing General Partner of JALAA Equities, LP (since 1997), a private hedge fund focused on the biotechnology and specialty pharmaceutical sector. Mr. Aryeh also serves on the Board of Directors of Ligand Pharmaceuticals Incorporated (since 2006), a public biotechnology company (“Ligand”), CorMatrix Cardiovascular (since 2010), a privately-held medical device company, and the Cystic Fibrosis Foundation's Therapeutics Board (since 2011). Previously, Mr. Aryeh served as a Director of both Nabi Biopharmaceuticals, prior to its merger with Biota Pharmaceuticals, Inc. (“Biota”) in November 2012, and of Myrexis, Inc. (2011 to 2013), both of which are public biotechnology companies. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.

Michael Price

Mr. Michael Dennis Price is Chief Financial Officer, Senior Vice President of the Company., effective on December 4, 2017. Michael Price was most recently vice president and chief financial officer for Noven Pharmaceuticals, Inc., a NASDAQ-listed company until its acquisition by Hisamitsu Pharmaceutical Company. Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. In his role at Noven, Mr. Price was directly involved with the development and execution of strategy that scaled the Company's commercial organization and significantly increased revenues. Prior to Noven, Mr. Price was vice president, chief financial officer, treasurer, secretary and a member of the board of directors for Bentley Pharmaceuticals, a New York Stock Exchange-listed company until Teva Pharmaceutical Industries' 2008 acquisition. Mr. Price is a certified public accountant. He holds a bachelor of science degree in business administration (accounting) from Auburn University and a master of business administration degree from Florida State University.

Gregory Perry

Mr. Gregory D. Perry is no longer Chief Financial and Administrative Officer of the Company, effective November 29, 2016 and serve as Principal Financial Officer of Novelion. Mr. Perry served as Aegerion’s Chief Financial and Administrative Officer prior to the Merger and as Chief Financial Officer of Eleven Biotherapeutics, Inc. from January 2014 until July 2015, when he joined Aegerion as Chief Financial Officer. Prior to joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics Holdings Corp. from September 2013 until December 2013. Before joining InVivo, he served as the Executive Vice President and Chief Financial Officer of ImmunoGen, Inc. Mr. Perry currently serves on the board of directors of Merus N.V. and previously served on the board of directors of Ocata Therapeutics, Inc., prior to its acquisition by Astellas Pharma Inc. in February 2016. He received a B.A. from Amherst College.

Jeffrey Hackman

Mr. Jeffrey S. Hackman is Chief Operating Officer, Executive Vice President of the Company. He served as senior vice president, head of U.S. internal medicine and oncology franchises for Shire Inc. from June 2016 to October 2017. Before joining Shire in 2016, Mr. Hackman served as vice president and region head, for North America at Baxalta US Inc. from May 2015 to June 2016. From 2012 to 2015, he was the senior vice president of commercial operations, chief operating officer and a member of the board of directors at Sigma-Tau Pharmaceuticals, Inc. Mr. Hackman has also held senior commercial leadership positions with Intercell USA, Inc., Emergent Biosolutions Inc., MedImmune, Inc., and Sanofi Pasteur. Mr. Hackman holds a bachelor of arts degree in communications from Lycoming College.

Barbara Chan

Ms. Barbara Y. Chan serves as Chief Accounting Officer of the Company. She was appointed President and Chief Accounting Officer of Aegerion, effective December 1, 2016. Ms. Chan serve as the Principal Accounting Officer of Novelion. Ms. Chan served as Aegerion’s Vice President, Chief Accounting Officer prior to the Merger and held a series of positions with PAREXEL International Corporation, most recently as Senior Director, Worldwide Accounting Services, from September 2013 until May 2016, when she joined Aegerion. Prior to joining PAREXEL, Ms. Chan served as Director, Americas and Asia Pacific Accounting at Nuance Communications, Inc. from June 2011 through August 2013. Ms. Chan holds B.S. and M.S. degrees from Bentley College and is a Certified Public Accountant in Massachusetts.

Suzanne Bruhn

Dr. Suzanne Louise Bruhn, Ph.D., serves as Director of the company effect on October 1, 2017. She has served as President and Chief Executive Officer of Proclara Biosciences, Inc. since April 2017. Between May 2012 and November 2015, Dr. Bruhn served as President and Chief Executive Officer of Promedior, Inc. She also served as a member of the board of directors of Raptor Pharmaceuticals Corp., a publicly traded pharmaceutical company, from April 2011 until it was acquired by Horizon Pharma plc in October 2016. Prior to that, Dr. Bruhn served as Senior Vice President, Strategic Planning and Program Management at Shire plc, a publicly traded biopharmaceutical company, between December 1998 and February 2012. Dr. Bruhn currently also serves on the board of directors of Aeglea BioTherapeutics, Inc., a publicly traded biotechnology company focused on the treatment of rare genetic diseases and cancer, and Pliant Therapeutics, a private biotechnology company. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology.

Mark Corrigan

Dr. Mark H.N. Corrigan, M.D. serves as Director of the Company. He currently serves on the board of directors of Cardiome Pharma Corp. (a public cardiovascular therapeutics company) and the supervisory board of Nabriva Therapeutics AG (a public biopharmaceutical company). From 2015 to March 2017, He served as a director of CoLucid Pharmaceuticals, Inc. (a public biopharmaceutical company), prior to its acquisition by Eli Lilly and Company. From 2014 to 2016, He served as chairman of the board of directors of EPIRUS Biopharmaceuticals, Inc. (“EPIRUS”). Prior to that, He served as President and Chief Executive Officer of Zalicus Inc. (“Zalicus”), from January 2010 until the completion of Zalicus’ merger with EPIRUS in July 2014. From 2013 to 2015, Dr. Corrigan served on the board of directors of Avanir Pharmaceuticals, Inc. (acquired by Otsuka Pharmaceuticals Co., Ltd.), a publicly traded company, chairing the Scientific Committee, and serving on the Nominating and Corporate Governance Committee. From 2008 to 2015, He served on the board of directors of Cubist Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.), a publicly traded biopharmaceutical company, serving on the Audit Committee and the Nominating and Governance Committee and chairing the Scientific Affairs Committee. From 2003 to 2009, Dr. Corrigan was Executive Vice President, Research & Development of Sepracor, Inc. (now Sunovion Pharmaceuticals Inc.) (“Sunovion”). Prior to joining Sunovion, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology, before joining the pharmaceutical industry. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. Dr. Corrigan to serve as a member of the Compliance Committee.

Mark DiPaolo

Mr. Mark A. DiPaolo serves as Director of the company. . DiPaolo is a partner and the General Counsel of Sarissa Capital Management LP (“Sarissa Capital”), a registered investment advisor, since 2013. From 2005 to 2013, Mr. DiPaolo served as a senior member of Icahn Capital Management LP’s management team, working on investing aspects of Carl Icahn’s activist strategy. Prior to working with Icahn Capital Management LP, Mr. DiPaolo was an attorney with Willkie Farr & Gallagher LLP. Mr. DiPaolo received his B.A. degree from Fordham University and his J.D. degree from Georgetown University Law Center. Mr. DiPaolo has substantial experience in operations, transactions, law and corporate governance.

Kevin Kotler

John Orloff

Dr. John J. Orloff, M.D is Director of the company. He had served as the Company’s Executive Vice President, Head of Research and Development since joining the Company following its acquisition of Aegerion Pharmaceuticals, Inc., where Dr. Orloff had been Executive Vice President, Research and Development since November 2016. Dr. Orloff previously served as Executive Vice President, Global Head of Research and Development and Chief Scientific Officer of Baxalta, Inc. (“Baxalta”) from July 2015 to June 2016. Dr. Orloff served as Global Head of R&D for Baxter BioSciences (“Baxter”) from July 2014 to June 2015, prior to Baxter’s spinout of Baxalta. Prior to Baxter, he served as senior vice president, global head of clinical development at Merck Serono Pharmaceuticals from January 2014 to May 2014. Between 2003 and 2013, Dr. Orloff held a series of positions at Novartis Pharma AG, including senior vice president and chief medical officer. Dr. Orloff completed his internal medicine residency at University of Pittsburgh Medical Center and his endocrinology and metabolism fellowship at Yale University School of Medicine, where he also spent seven years on the faculty. He holds an M.D. from University of Vermont College of Medicine and a B.A. from Dartmouth College. The Board has concluded that Dr. Orloff is well-qualified to serve on the Board and has the requisite qualifications, skills and perspectives derived from his extensive experience in the biopharmaceutical industry, including as an executive officer of the Company, as well as his scientific background.

Donald Stern

Anne VanLent

Stephen Sabba

Dr. Stephen L. Sabba, M.D. is an Independent Director of the Company. Currently, Dr. Sabba is also a Partner and Health Care Portfolio Manager at Knott Partners, LP (since 2006), an investment fund, and a Director of Ligand (since 2008), a public biotechnology company. Previously, he was a Partner and Director of Research with Kilkenny Capital Management (2001 to 2006), a Chicagobased hedge fund. Dr. Sabba received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a Bachelor of Science degree with honors at Cornell University.

John Thomas

Mr. John C. Thomas, Jr., is an Independent Director of the company. Mr. Thomas has more than 38 years of experience in a variety of financial and accounting positions, with the last 27 years spent in the medical, pharmaceutical and device fields. Currently, Mr. Thomas also serves as Chief Financial Officer, Secretary and Director of CorMatrix (since 2001), a privately-held medical device company, and as Chief Financial Officer, Secretary and Director of Motion Reality, Inc. (since 1991), a motion capture and simulation company. In the past ten years, Mr. Thomas served as acting Chief Financial Officer for DemeRx, Inc. (2010 to 2011); as Chief Financial Officer for MRI Interventions, Inc. (1998 to 2010), MiMedx Group, Inc. (2007 to 2008) and DARA BioSciences (2003 to 2009); and as a director of MRI Interventions, Inc. (2004 to 2011) and DARA BioSciences (2012). Previously, Mr. Thomas also served as a Trustee and subsequently the Chairman of the Finance Committee of The Walker School, a private Pre-K through 12 grade school (1999 to 2012). Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia, McIntire School of Commerce with a Bachelor of Science in Commerce (with distinction) degree in 1975.